Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET

Company Participants

Dan O’Connell - Chief Executive Officer
Matt Zuga - Chief Financial Officer, Chief Business Officer
Dr. Jim Doherty - President, Chief Development Officer
Dr. Eric Siemers - Chief Medical Officer.
Alex Braun - Head of Investor Relations

Conference Call Participants

Tom Shrader - BTIG
Cameron Bozdog - Bank of America
Samantha Schaeffer - Cantor Fitzgerald
Trung Huynh - UBS
Ananda Ghosh - HC Wainwright

Operator

Hello, and thank you for standing by. Welcome to Acumen Pharmaceuticals Q2 2024 conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions].

I would now like to turn the call over to Alex Braun, Head of Investor Relations. Please go ahead.

Alex Braun

Thank you, operator. Good morning and welcome to the Acumen conference call to discuss our business update and financial results for the quarter-ended June 30, 2024.

With me today are Dan O’Connell, our CEO; and Matt Zuga, our CFO and Chief Business Officer. Dan and Matt have some prepared remarks, and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our President and Chief Development Officer, and Dr. Eric Siemers, our Chief Medical Officer.

Before we begin, we encourage listeners to go to the Investor's section of the Acumen website to find our press release issued this morning that we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans.

These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Please see slide two of our corporate presentation, our press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements.

We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments.

And with that, I'll turn the call over to Dan.

Dan O’Connell

Thanks Alex. Good morning, everyone, and thanks for joining us today. We've made significant progress in the first half of 2024 as we continue to execute our clinical plans for sabirnetug, our next generation, amyloid beta oligomers targeted antibody for the treatment of early Alzheimer's disease.